allergen immunotherapy: a practice parameter second update

Download Allergen immunotherapy: A practice parameter second update

Post on 07-May-2015



Health & Medicine

13 download

Embed Size (px)


  • 1.Allergen immunotherapy: A practice parametersecond updateSupplement Editor: Linda Cox, MDCo-editors: James T. Li, MD, Harold Nelson, MD, and Richard Lockey, MD These parameters were developed by the Joint Task Force onparameters by the AAAAI or the ACAAI should be directed to the Practice Parameters, representing the American Academy of Executive Ofces of the AAAAI, the ACAAI, and the Joint Council Allergy, Asthma and Immunology; the American College of Allergy,of Allergy, Asthma and Immunology. These parameters are not Asthma and Immunology; and the Joint Council of Allergy, Asthma designed for use by pharmaceutical companies in drug promotion. and Immunology. Published practice parameters of the Joint Task Force The American Academy of Allergy, Asthma and Immunologyon Practice Parameters for Allergy and Immunology (AAAAI) and the American College of Allergy, Asthma and include the following: Immunology (ACAAI) have jointly accepted responsibility for establishing the Allergen immunotherapy: a practice parameter1. Practice parameters for the diagnosis and treatment second update. This is a complete and comprehensive document at of asthma. J Allergy Clin Immunol 1995;96(suppl): the current time. The medical environment is a changing S707-S870. environment, and not all recommendations will be appropriate for2. Practice parameters for allergy diagnostic testing. all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served Ann Allergy 1995;75:543-625. on the Joint Task Force, is authorized to provide an ofcial AAAAI 3. Practice parameters for the diagnosis and management or ACAAI interpretation of these practice parameters. Any request of immunodeciency. Ann Allergy 1996;76:282-94. for information about or an interpretation of these practice 4. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol 1996;98:1001-11.5. Disease management of atopic dermatitis: a practice Disclosure of potential conict of interest: L. Cox has consulting arrangements parameter. Ann Allergy 1997;79:197-211.with Allergy Therapeutics, Genentech/Novartis, and Greer Laboratories and 6. The diagnosis and management of on the speakers bureau for Genentech/Novartis, GlaxoSmithKline, andAstraZeneca. R. Lockey has received grant support from Greer Laboratories; J Allergy Clin Immunol 1998;101(suppl):S465-S528.served as chairman of an advisory committee for ALK-Abello for over7. Algorithm for the diagnosis and management of7 years; and has served as an expert witness for allergen immunotherapyasthma: a practice parameter update. Ann Allergydeath for both plaintiff and defendant. H. Nelson has consulting arrange-1998;81:415-20.ments with Genentech/Novartis, Curalogic, GlaxoSmithKline, Inazyme8. Diagnosis and management of rhinitis: parameterPharmaceuticals, Dey Laboratories, Dynavax Technologies, Altana, andSchering-Plough; has received grant support from Dey Laboratories, documents of the Joint Task Force on PracticeIVAX, MediciNova, Wyeth, Sepracor, Genentech, Schering-Plough, No- parameters in Allergy, Asthma and Immunology.vartis, AstraZeneca, SkyPharma, Altana, and Roche; and is on the speakers Ann Allergy 1998;81(suppl):S463-S518.bureau for GlaxoSmithKline and AstraZeneca. D. Bernstein has consulting 9. Parameters for the diagnosis and management ofarrangements with ALK-Abello and has received grant support fromDynavax and ALK-Abello. J. Blessing-Moore has received grant support sinusitis. J Allergy Clin Immunol 1998;102(suppl):from Novartis-Genentech and AstraZeneca and is on the speakers bureau S107-S144.for Schering-Plough, Merck, Aventis, Novartis/Genentech, AstraZeneca.10. Stinging insect hypersensitivity: a practice parameter.D. M. Lang has consulting arrangements with, has received grant supportJ Allergy Clin Immunol 1999;103:963-80.from, and is on the speakers bureau for GlaxoSmithKline, Merck, Astra- 11. Disease management of drug hypersensitivity: aZeneca, Centocor, Sano-Aventis, Schering-Plough, Verus, and Dey. J.Oppenheimer has consulting arrangements with GlaxoSmithKline, Astra- practice parameter. Ann Allergy 1999;83(suppl):Zeneca, Sepracor, and Merck; has received grant support from AstraZeneca,S665S700.Sepracor, and Merck, Boehringer Ingelheim, Novartis/Genentech, and 12. Diagnosis and management of urticaria: a practiceSchering-Plough; and is on the speakers bureau for GlaxoSmithKline, parameter. Ann Allergy 2000;85(suppl):S521-S544.AstraZeneca, Sepracor, and Merck. J. M. Portnoy has consulting arrange-ments with Greer and GlaxoSmithKline; has received grant support from 13. Allergen immunotherapy: a practice parameter. AnnClorox; and is on the speakers bureau for Schering-Plough, Merck, Aventis,Allergy 2003;90(suppl):SI-S540.Secpracor, and AstraZeneca. S. A. Tilles has consulting arrangements with14. Symptom severity assessment of allergic rhinitis:Genentech, Schering-Plough, and GlaxoSmithKline; has received grant sup- part I. Ann Allergy 2003;91:105-14.port from AstraZeneca, Novartis, Medpoint, Apieron, and ALK-Abello; and 15. Disease management of atopic dermatitis: an updatedis on the speakers bureau for GlaxoSmithKline, Pzer, Genentech, andAlcon. The rest of the authors have declared that they have no conict ofpractice parameter. Ann Allergy 2004;93(suppl):interest.S1-S21. Reprint requests: Joint Council of Allergy, Asthma and Immunology, 50 N 16. Stinging insect hypersensitivity: a practice parameterBrockway St, #3-3, Palatine, IL 60067. update. J Allergy Clin Immunol 2004;114:869-86. J Allergy Clin Immunol 2007;120:S25-85. 0091-6749/$32.00 17. The diagnosis and management of anaphylaxis: an 2007 American Academy of Allergy, Asthma & Immunology updated practice parameter. J Allergy Clin Immunol doi:10.1016/j.jaci.2007.06.0192005;115(suppl):S483-S523. S25

2. S26 Cox et alJ ALLERGY CLIN IMMUNOLSEPTEMBER 2007 18. Practice parameter for the diagnosis and managementUniversity of Cincinnati College of Medicine of primary immunodeciency. Ann Allergy 2005;Cincinnati, Ohio 94(suppl):S1-S63.I. Leonard Bernstein, MD 19. Attaining optimal asthma control: a practice parame- Departments of Medicine and Environmental Health ter. J Allergy Clin Immunol 2005;116(suppl):S3-S11.University of Cincinnati College of Medicine 20. The diagnosis and management of sinusitis: a practiceCincinnati, Ohio parameter update. J Allergy Clin Immunol 2005; David A. Khan, MD 116(suppl):S13-S47.Department of Internal Medicine 21. Food allergy: a practice parameter. Ann AllergyUniversity of Texas Southwestern Medical Center Asthma Immunol 2006;96(suppl 2):S1-S68.Dallas, Tex 22. Contact dermatitis: a practice parameter. Ann AllergyJoann Blessing-Moore, MD Asthma Immunol 2006;97(suppl 2):S1-S38.Departments of Medicine and PediatricsStanford University Medical CenterThese parameters are also available on the internet atDepartment of Immunology Alto, CalifDavid M. Lang, MD CONTRIBUTORS Allergy/Immunology SectionDivision of MedicineThe Joint Task Force has made a concerted effort to Allergy and Immunology Fellowship Training Program acknowledge all contributors to this parameter. If any Cleveland Clinic Foundation contributors have been excluded inadvertently, the TaskCleveland, Ohio Force will ensure that appropriate recognition of such Richard A. Nicklas, MD contributions is made subsequently.Department of MedicineThe Joint Task Force gratefully acknowledges theGeorge Washington Medical Center American Academy of Allergy, Asthma and Immunology Washington, DC Board of Directors and the American College of Allergy,John Oppenheimer, MD Asthma and Immunology Board of Regents for their Department of Internal Medicine review and support of this document. New Jersey Medical SchoolPulmonary and Allergy Associates SUPPLEMENT EDITORMorristown, NJJay M. Portnoy, MD Linda Cox, MDSection of Allergy, Asthma & Immunology Department of Medicine The Childrens Mercy Hospital Nova Southeastern University College of OsteopathicDepartment of Pediatrics Medicine University of Missouri-Kansas City School of Medicine Davie, Fla Kansas City, MoDiane E. Schuller, MDDepartment of Pediatrics CO-EDITORS Pennsylvania State University Milton S. Hershey Medical College James T. Li, MD, PhD Hershey, Pa Division of Allergic DiseasesSheldon L. Spector, MD Mayo ClinicDepartment of Medicine Rochester, MinnUCLA School of Medicine Richard Lockey, MD Los Angeles, Calif Departments of Medicine, Pediatrics, and Public Health Stephen A. Tilles, MD Division of Allergy and Immunology Department of Medicine University of South Florida College of MedicineUniversity of Washington School of Medicine James A. Haley Veterans HospitalRedmond, Wash Tampa, Fla Dana V. Wallace, MD Harold Nelson, MDNova Southeastern University Department of Medicine Davie, Fla National Jewish Medical and Research Center Denver, Colo INVITED REVIEWERS JOINT TASK FORCE REVIEWERSDon Aaronson, MD, Chicago, Ill David Bernstein, MDDavid Golden, MD, Baltimore, Md Department of Medicine and Environmental HealthMoises Calderon, MD, London, United Kingdom (UK) 3. J ALLERGY CLIN IMMUNOL Cox et al S27 VOLUME 120, NUMBER 3 Stephen Durham, MD, London, UK process consistent with recommendations of the Ira Finegold, MD, New York, NY American College of Medical Qualitys Policy on de- Stephen Kemp, Jackson, Missvelopment and use of practice parameters for medical Brian Smart, MD, Glen Ellyn, Ill quality decision-making (Appendix 1).1 Mark L. Vandewalker, MD, Columbia, Mo This document builds on the previous Joint Task Force Richard Weber, MD, Denver, Colodocument, Allergen immunotherapy: a practice param- David Weldon, MD, College Station, Tex eter published in the Annals of Allergy, Asthma andImmunology in 2003.2 The updated practice parametersdraft was prepared by Drs Linda Cox, James Li, Hal REVIEWERS OF ALLERGEN EXTRACTNelson, and Richard Lockey. The Joint Task Force SECTIONrework

View more >